About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
  • Cereblon/E3 Ligase Modulation

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    Ikaros and Aiolos (encoded by the genes IKZF1 and IKZF3, respectively) are members of the Ikaros family of zinc-finger transcription factors and are responsible for lymphocyte differentiation and B-cell development.1,2 Genome-wide association studies have shown that polymorphisms in IKZF1 and IKZF3 correlated with an increased risk for developing systemic lupus erythematosus (SLE),1-4 and Ikaros and Aiolos were overexpressed in the peripheral blood of patients with SLE, as compared to healthy controls.1,2 Aiolos is required for the production of long-lived, high-affinity plasma cells and Ikaros may play a role in the development of plasmacytoid dendritic cells.1,2

    Ikaros and Aiolos are substrates of the cullin ring ligase 4 (CRL4CRBN) E3 ubiquitin ligase complex.5 Cereblon (CRBN) is the target protein receptor on CRL4CRBN that includes cullin 4A (CUL4), DNA damage-binding protein 1 (DBB1), and regulator of cullin 1 (ROC1).1,6 Preclinical studies suggest that immunomodulatory agents can co-opt CRBN and modulate its function to redirect target proteins for ubiquitination and proteasomal degradation.5,7,8 Ikaros and Aiolos are recruited to CRL4CRBN in T cells for proteasomal degradation.5

    Based on preclinical studies, the roles of Ikaros and Aiolos in the regulation and homeostasis of the immune system suggest that CRBN may be redirected for therapeutic purposes in immune-mediated disorders such as SLE.

    AutoAbs, autoantibodies CRBN, cereblon; CRL4, cullin ring ligase 4; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IgG, immunoglobulin G; IgM, immunoglobulin M; IL, interleukin; IM, immunoglobulin TNF, tumor necrosis factor

    View Related Molecules

    References

    1. Schafer PH, et al. Ann Rheum Dis. 2018;77:1516-1523. PMID:29945920
    2. Nakayama Y, et al. J Immunol. 2017;199(7):2388-2407. PMID:28848067
    3. Cunnighame Graham DS, et al. PLoS Genet. 2011;7:e1002341. PMID:22046141
    4. Lessard CJ, et al. Am J Hum Genet. 2012;90:648-660. PMID:22464253
    5. Gandhi AK, et al. Br J Haematol. 2014;164:811-821. PMID:24328678
    6. Ito T, et al. Science. 2010;327:1345-1350. PMID:20223979
    7. Krönke J, et al. Science. 2014;343:301-305. PMID:24292625
    8. Lu G, et al. Science. 2014;343:305-309. PMID:24292623